Welcome to our dedicated page for RAYMOND JAMES FINANCIAL SEC filings (Ticker: RJF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on RAYMOND JAMES FINANCIAL's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into RAYMOND JAMES FINANCIAL's regulatory disclosures and financial reporting.
Raymond James Financial director Art A. Garcia acquired 1,303 Deferred Restricted Stock Units (DRSUs) as part of his Board compensation. These DRSUs convert into an equal number of common shares, plus cash in lieu of dividends, when they vest.
The units vest at the next annual shareholders meeting following the grant, but no later than March 15 of the following calendar year. Settlement of the vested DRSUs is deferred until Garcia leaves the Board, and his directly held common stock, including DRSUs, totals 6,992 shares after this grant.
Raymond James Financial director Benjamin Esty received an equity grant rather than buying shares on the market. He was awarded 1,303 Deferred Restricted Stock Units (DRSUs) as part of his Board compensation, which will convert one-for-one into common shares after vesting and later settlement. Following this grant, he holds 31,794 common shares, including DRSUs, with vesting tied to the next annual shareholders meeting and settlement deferred until he leaves the Board.
RAYMOND JAMES FINANCIAL INC director Cecily Mistarz reported equity-based compensation and related conversions on 2026-02-19. She acquired Restricted Stock Units through grants and exercised other RSUs that convert into common stock on a one-to-one basis with additional cash in lieu of dividends.
The transactions included a grant of 1,303 shares of common stock as part of compensation for Board service and multiple RSU awards and exercises at a reported price of $0.0000 per unit or share. Deferred Restricted Stock Units vest at the next annual shareholders meeting and, per her election, some will settle two years after vesting.
Raymond James Financial director Jeffrey N. Edwards reported equity compensation activity involving restricted stock units (RSUs) and common stock. He received a grant of 1,303 RSUs, each representing a contingent right to one share of common stock plus accrued cash in lieu of dividends.
The new RSU award will vest at the date of the next annual shareholders meeting, but no later than March 15, 2027. On the same date, 1,253 previously granted RSUs vested and were exercised into 1,253 shares of common stock at a stated price of $0.00 per share.
Raymond James Financial director Marlene Debel reported equity awards tied to company stock. She received a grant of 1,303 Restricted Stock Units on February 19, 2026, with each unit representing one share of common stock plus accrued cash in lieu of dividends upon vesting.
The award will vest at the date of the next annual shareholders meeting, but no later than March 15, 2027. On the same date, 1,253 previously granted RSUs vested and were converted into 1,253 shares of common stock at a price of $0.00 per share, bringing her direct holdings to 8,820 common shares and 1,303 RSUs.
Begor Mark W reported acquisition or exercise transactions in this Form 4 filing.
Raymond James Financial director Mark W. Begor received an equity grant in the form of deferred restricted stock units. On 19 Feb 2026 he was awarded 1,303 common stock units at no cash cost, bringing his directly held units and shares to 2,285. These DRSUs vest at the next annual shareholders meeting (or by March 15 following grant) and will be settled after he leaves the Board.
Raymond James Financial, Inc. reported the results of its 2026 Annual Meeting of Shareholders and declared a quarterly cash dividend. Shareholders elected twelve directors, each receiving a clear majority of votes cast, with broker non-votes of 23,954,132 reported for the director elections.
Shareholders approved, on an advisory non-binding basis, the compensation of named executive officers with 94.74% of votes cast in favor. They also approved the Amended and Restated 2012 Stock Incentive Plan and the Amended and Restated 2003 Employee Stock Purchase Plan with 95.32% and 99.39% support, respectively.
In addition, shareholders ratified the appointment of KPMG LLP as independent registered public accounting firm for the fiscal year ending September 30, 2026, with 95.37% of votes cast in favor. The Board declared a quarterly cash dividend of $0.54 per share, payable April 15, 2026 to shareholders of record on April 1, 2026.
Raymond James Financial reported strong January 2026 operating trends, highlighted by record client assets under administration of $1.80 trillion, up 13% from January 2025 and 2% from December 2025, driven mainly by higher equity markets and net asset inflows.
Private Client Group assets under administration reached $1.74 trillion, up 14% year-over-year and 2% sequentially, while fee-based PCG assets rose 18% year-over-year to $1.06 trillion. Financial assets under management increased 14% to $286.4 billion and bank loans grew 13% to $53.8 billion. Clients’ domestic cash sweep and Enhanced Savings Program balances declined to $55.0 billion, down 4% year-over-year and 5% from December, reflecting seasonal fee collections and client reinvestment. The company noted that this limited operating data should not be assumed to correlate consistently with earnings.
Raymond James Financial Inc. filed a Form 13F-HR reporting holdings as an institutional investment manager. The report lists 13,038 Form 13F information table entries with a total market value of $321,406,094,145. The filing names 13 other included managers.
The report indicates a change in reporting structure starting with the quarter ending December 31, 2024, with certain subsidiaries filing separately as described.
Raymond James Financial, Inc. reported solid results for the quarter ended December 31, 2025, with revenue growing while earnings eased slightly. Total revenues rose to $4.176 billion from $4.035 billion, driven mainly by higher asset management fees of $1.999 billion and stronger brokerage revenues.
Net income was $563 million, down from $600 million a year earlier, as non-interest expenses increased to $3.007 billion. Diluted EPS was $2.79 versus $2.86. The bank loan portfolio expanded to $53.7 billion held for investment, while bank deposits grew to $60.2 billion, with approximately 83% FDIC-insured. Shareholders’ equity rose to $12.6 billion, and the firm repurchased 2.5 million common shares during the quarter. Raymond James also highlighted pending acquisitions of GreensLedge and Clark Capital, expected to close in fiscal 2026, to deepen capabilities in securitization and asset management.